# UCB

Type: Company (UCB.BR)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/ucb
Canonical HTML page: https://getbiobrief.com/entity/ucb

## Timeline

- **2026-12-31**: Profitability Target — Antengene aims to achieve its first full year of profitability.
- **2026-04-01**: AACR 2026 — Antengene scheduled to present data on next-generation ADCs and TCEs.
- **2026-03-20**: 2025 FY Results — Company announces full-year results and confirms shift toward 2026 profitability.
- **2026-03-04**: Investor Briefings — Antengene hosts dual-language conference calls to discuss the UCB partnership and pipeline impact.
- **2026-03-04**: UCB Partnership — Antengene enters into a global license agreement with UCB for ATG-201 for $60M upfront.
- **2026-03-03**: Global License Agreement — Antengene and UCB announce the $1.1B+ licensing deal for ATG-201.
- **2026-Q1**: Regulatory Filings — Planned submission of clinical trial applications for ATG-201 in China and Australia.

## Recent coverage (3 stories)

### UCB Commits $2B to Atlanta Manufacturing Hub to Fuel U.S. Growth
2026-03-24 23:54:36 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Belgian biopharma leader UCB has announced a massive $2 billion investment to construct a new manufacturing facility in suburban Atlanta, Georgia. The project is expected to create 330 high-tech jobs and significantly enhance the company's production capacity for its growing immunology and neurology portfolios.
Full story: https://getbiobrief.com/story/ucb-atlanta-manufacturing-expansion-2-billion

### Antengene Eyes 2026 Profitability Following Landmark TCE Out-Licensing Deal
2026-03-20 14:54:16 · Sentiment: Positive · Impact: 6/10 · Sources: 3

Antengene Corporation has reported its 2025 full-year financial results, highlighted by the first successful out-licensing of its proprietary T-cell engager (TCE) platform. This strategic milestone validates the company's R&D capabilities and establishes a clear path toward projected profitability by 2026.
Full story: https://getbiobrief.com/story/antengene-2025-results-tce-licensing-profitability

### UCB and Antengene Ink $1.1B Deal for CD19 Bispecific in Autoimmune Pivot
2026-03-04 00:38:57 · Sentiment: Positive · Impact: 7/10 · Sources: 2

Antengene has granted UCB exclusive global rights to ATG-201, a CD19/CD3 bispecific T-cell engager, in a deal worth up to $1.18 billion. The partnership leverages Antengene's AnTenGager platform to target B-cell-driven autoimmune diseases, marking a major strategic expansion for both firms.
Full story: https://getbiobrief.com/story/ucb-antengene-atg201-licensing-deal-autoimmune

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.